Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
New cancer drugs linked to fewer arrhythmias
Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.
Key clinical point: The novel targeted cancer therapies cause markedly fewer cardiac arrhythmias.
Major finding: Cancer patients treated with a tyrosine kinase inhibitor, immune checkpoint inhibitor, or another of the novel targeted therapies were 40% less likely than were those on anthracycline-based therapy to develop a treatment-induced cardiac arrhythmia up to 6 months after treatment initiation.
Study details: This was a retrospective single-center study including more than 5,000 cancer patients.
Disclosures: The presenter reported having no financial conflicts regarding his study, which was conducted free of commercial support.
Source: Nickel A et al. ACC 18, Abstract #900-06.
Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.
